This 2018 photo provided by Amylyx shows the company's co-founders Joshua Cohen, left, and Justin Klee in Cambridge, Mass. On Friday, Sept. 2, 2022, federal health regulators remain unconvinced about the benefits of a closely watched experimental drug for the debilitating illness known as Lou Gehrig’s disease, even as they're set to give its maker, Amylyx, a rare second chance to make its case publicly. (Amylyx via AP)
Ovechkin scoring another game-winning goal for the Capitals comes as no surprise to the Predators Shares
4 astronauts return to Earth after being delayed by Boeing's capsule trouble and Hurricane Milton Shares
Quarter Pounders are off the menu at 20% of McDonald's in US as E. coli cases are investigated Shares